Moderna to Commence Late-stage COVID-19 Vaccine Trial on 27 July, 2020

 Moderna to Commence Late-stage COVID-19 Vaccine Trial on 27 July, 2020

Moderna Anticipate Commencing of Late-stage COVID-19 Vaccine Trial on 27 July, 2020

Shots:

  • Moderna has reported the robust results of its ongoing P-I study that demonstrated mRNA-1273 at (25-, 100- & 250-mcg dose levels) induced anti–SARS-CoV-2 immune responses in all participants with no trial-limiting safety concerns. These results were published in NEJM
  • All participants seroconverted by the 15-day mark. Post two vaccinations, @57day, geometric mean titers exceeded those seen in convalescent sera obtained from 38 patients with confirmed COVID-19. The mRNA-1273 elicited neutralizing Abs titers, post two vaccination with neutralizing activity against SARS-CoV-2 in all evaluated participants @43day
  • Based on P-I interim analysis data, Moderna’s CMO has supported the choice of mRNA-1273 (100mcg) in a prime and boost regimen as the optimal dose for the P-III study scheduled to begin July 27, 2020

Click here to read full press release/ article | Ref: NEJM | Image: Moderna

Related News: Moderna Reports Positive Interim P-I Data of mRNA-1273 Against COVID-19

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post